A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity
(DLT) of recombinant humanized PD-L1/4-1BB bispecific antibody (ES101) in patients with
advanced solid tumors.